Literature DB >> 19273219

Role of Toll-like receptor mediated signaling pathway in ischemic heart.

Yasuchika Takeishi1, Isao Kubota.   

Abstract

Stimulation of TLRs by exogenous and endogenous ligands triggers expression of several genes that are involved in innate immune responses. Recently, a role of TLR4 in the myocardial response to injury separate from microbial pathogens has been examined in experimental studies. TLR4 deficient mice sustain significantly smaller infarctions compared with wild-type control mice given similar areas at risk. Levels of serum cytokines such as IL-1b, IL-6, and TNFa are increased after ischemia/reperfusion, but these responses are attenuated in TLR4 deficient mice compared to control mice. TLR2 signaling also importantly contributes to cardiac dysfunction following ischemia/reperfusion. MyD88, a key adaptor protein for TLR signaling, is responsible for the protective effects of TLR signaling inhibition in ischemia/reperfusion injury. TLR4 gene polymorphism (Asp299Gly) attenuates innate immune responsiveness, reduces the risk for coronary artery disease, and increases a chance of longevity. The innate immune system is clearly involved in the pathogenesis of cardiovascular diseases and could be a new therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273219     DOI: 10.2741/3397

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  12 in total

Review 1.  Toll-like receptors: new players in myocardial ischemia/reperfusion injury.

Authors:  Tuanzhu Ha; Li Liu; Jim Kelley; Race Kao; David Williams; Chuanfu Li
Journal:  Antioxid Redox Signal       Date:  2011-04-08       Impact factor: 8.401

2.  Helicobacter infection alters MyD88 and Trif signalling in response to intestinal ischaemia-reperfusion.

Authors:  Sara M Hoffman; Hua Wang; Michael R Pope; Sherry D Fleming
Journal:  Exp Physiol       Date:  2010-11-05       Impact factor: 2.969

3.  Toll-like receptor 4 signaling in dysfunction of cardiac microvascular endothelial cells under hypoxia/reoxygenation.

Authors:  Zheng Zhang; Weijie Li; Dongdong Sun; Li Zhao; Rongqing Zhang; Yabin Wang; Xuan Zhou; Haichang Wang; Feng Cao
Journal:  Inflamm Res       Date:  2010-07-23       Impact factor: 4.575

4.  TLR2 modulates antibodies required for intestinal ischemia/reperfusion-induced damage and inflammation.

Authors:  Michael R Pope; Sherry D Fleming
Journal:  J Immunol       Date:  2014-12-24       Impact factor: 5.422

Review 5.  The paradoxical role of inflammation in cardiac repair and regeneration.

Authors:  Bingbing Jiang; Ronglih Liao
Journal:  J Cardiovasc Transl Res       Date:  2010-05-07       Impact factor: 4.132

6.  HSP90 inhibition by 17-DMAG reduces inflammation in J774 macrophages through suppression of Akt and nuclear factor-κB pathways.

Authors:  Samuel K Shimp; Carl D Parson; Nicole L Regna; Alicia N Thomas; Cristen B Chafin; Christopher M Reilly; M Nichole Rylander
Journal:  Inflamm Res       Date:  2012-02-12       Impact factor: 4.575

Review 7.  Minireview: Won't get fooled again: the nonmetabolic roles of peroxisome proliferator-activated receptors (PPARs) in the heart.

Authors:  Pamela Lockyer; Jonathan C Schisler; Cam Patterson; Monte S Willis
Journal:  Mol Endocrinol       Date:  2009-12-16

8.  TLR9 is dispensable for intestinal ischemia/reperfusion-induced tissue damage.

Authors:  Emily Archer Slone; Michael R Pope; Mary Roth; Ruth Welti; Sherry D Fleming
Journal:  Am J Clin Exp Immunol       Date:  2012

Review 9.  Endogenous toll-like receptor ligands and their biological significance.

Authors:  Li Yu; Liantang Wang; Shangwu Chen
Journal:  J Cell Mol Med       Date:  2010-11       Impact factor: 5.310

10.  SNP-SNP Interaction between TLR4 and MyD88 in Susceptibility to Coronary Artery Disease in the Chinese Han Population.

Authors:  Dandan Sun; Liping Sun; Qian Xu; Yuehua Gong; Honghu Wang; Jun Yang; Yuan Yuan
Journal:  Int J Environ Res Public Health       Date:  2016-03-04       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.